You are here

Jon Goldstein


Goldstein JT, Berger AC, Shih J, et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 2017 Dec 15;77(24):6987-6998.

Hua Z, Huang X, Bregman H, et al. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorg Medicinal Chem Lett. 2012;22(17):5392–5395.

Huang H, Acquaviva L, Berry V,  et al. Structure-based design of potent and selective CK1γ inhibitors. ACS Med Chem Lett. 2012;3(12):1059–1064.

Jon Goldstein, Ph.D.

Jon Goldstein is a senior group leader in the Cancer Program of the Broad Institute of MIT and Harvard and a member of the Meyerson Lab. His research focuses on harnessing discoveries from large-scale sequencing of cancer genomes to identify and validate new candidate therapeutic drug targets and to translate these findings into genomically targeted drug discovery programs.

Prior to joining the Broad Institute in June 2014, Goldstein worked in the pharmaceutical industry as a senior scientist for various companies. During his tenure with Amgen, he worked on metabolic disorders and oncology therapeutic investigations; this was followed by a stint working on therapeutic antibody drug discovery at Abbott Laboratories/AbbVie. Goldstein is a member of the American Association for Cancer Research.

Goldstein holds a Ph.D. in biochemistry from University of Wisconsin, Madison, and a B.Sc. in chemistry from Western University (London, Ontario, Canada).

Contact Jon Goldstein via email at

July 2022